National panel lowers recommended mammogram screening age to 40

Breast cancer cases are increasing among younger women, and it now makes sense to start regular screening younger, the task force says. 

April 30, 2024 Check out STAT+

Sponsored By

Illustration: Christine Kao/STAT; Photos: Getty, AP, Adobe What we're starting to learn about H5N1 in cows, and the risk to people At this point in the H5N1-in-cows story, there are questions without solid answers, though some evidence is coming into focus. By Helen Branswell and Megan Molteni With younger women getting breast cancer, national panel lowers mammogram screening age to 40 A national advisory panel says new guidelines should save lives and reduce racial disparities in breast cancer. By Angus Chen DEA will move to reclassify marijuana in a historic shift, AP sources say Marijuana currently classified as a Schedule I drug alongside heroin and LSD. Moving to Schedule III would not legalize for recreational use. By Associated Press Scott Olson/Getty Images STAT+ | In a big reversal, Walmart to shut down medical clinics and online care The retail giant will shutter its network of health centers and telehealth business, citing low payments from health insurers and high costs to operate the clinics. By Bob Herman STAT+ | Eli Lilly raises earnings guidance as it ramps up Mounjaro, Zepbound manufacturing Zepbound, which was approved last November, brought in $517 million in sales in the first quarter of this year, more than analysts expected. By Elaine Chen Backers of menthol cigarette ban vow to keep up the fight, but concede it will be a long battle After the Biden administration delayed a ban on menthol cigarettes, several groups said they don't expect major action until after November. By Nicholas Florko Adobe STAT+ | Akili to lay off 46% of its staff, explore strategic options amid sluggish sales As sales slump, the prescription digital therapeutics maker lays off 46% of workforce, and will "evaluate potential strategic alternatives." By Mario Aguilar STAT+ | FTC issues warnings on 'junk' patent listings for Ozempic and other drugs "By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs," said FTC Chair Lina Khan. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser